EUCTR2013-004368-74-DEActive, not recruitingPhase 1
A phase 2 open-label multi-centre study to evaluate the efficacy and safety of Oxabact® to reduce plasma oxalate in patients with primary hyperoxaluria who are on dialysis
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 12
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1.Signed informed consent (as applicable for the age of the patient). An appendix to the informed consent form will be signed by patients continuing on treatment after week 14.
- •2.Male or female patients = 2 years of age. Patients have to be able to swallow size 4 capsules twice daily, or use a gastric tube that allows for administration of size 4 capsules.
- •3.A diagnosis of PH (as determined by standard diagnostic methods).
- •4.Patient should be on a stable dialysis regimen for at least two weeks before baseline.
- •5.Plasma oxalate =40 micromole/L prior to the dialysis session.
- •6.Patients receiving vitamin B6 must be receiving a stable dose for at least 3 months prior to screening and must remain on the stable dose during the study. Patients not receiving vitamin B6 at study entry must be willing to refrain from initiating vitamin B6 during study participation.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 11
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •7.Inability to swallow size 4 capsules twice daily, or using a gastric tube not suited for administration of size 4 capsules via the tube.
- •8.Ongoing treatment with immunosuppressive medication.
- •9.The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory bowel disease and short-bowel syndrome.
- •10.Use of antibiotics to which O. formigenes is sensitive (see section 7.2.2), including current antibiotic use, or antibiotics use within 14 days of initiating study medication.
- •11.Current treatment with a separate ascorbic acid preparation. Standard of care vitamin supplement for patients on dialysis are allowed.
- •12.Pregnancy.
- •13.Women of childbearing potential who are not using adequate contraceptive precautions. Sexually active females, unless surgically sterile or at least 2 years post-menopausal, must be using a highly effective contraception (including oral, transdermal, injectable, or implanted contraceptives, IUD, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 30 days prior to the first dose of OC5 and must agree to continue using such precautions during the clinical study.
- •14.Presence of a medical condition that the Principal Investigator considers likely to make the patient susceptible to adverse effect of study treatment or unable to follow study procedures.
- •15.Participation in any study of an investigational product, biologic, device, or other agent within 30 days prior to the first dose of OC5 or not willing to forego other forms of investigational treatment during this study.
Investigators
Similar Trials
Recruiting
Phase 2
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinomaadrenocortical carcinoma2024-517205-82-00Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy24
Active, not recruiting
Phase 1
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous CarcinomaCTIS2023-507324-23-00K-Group Beta Inc.120
Completed
Phase 2
Omacetaxine in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene MutatioACTRN12609000373279ChemGenex Pharmaceuticals Inc.100
Not yet recruiting
Unknown
A phase 2, multi-center, open-label study to evaluate the safety, tolerability and efficacy of combination regimen of GI-101A and SL-T10 in patients with metastatic castration-resistant prostate cancer (mCRPC)NeoplasmsKCT0008799Asan Medical Center72
Active, not recruiting
Phase 1
A phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects with Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities - NAPulmonary Arterial HypertensionEUCTR2005-001564-31-DEMyogen Inc.30